| Basics |
Esperion Therapeutics, Inc.
Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C.
|
| IPO Date: |
June 26, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$540.35M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.75 | 3.25%
|
| Avg Daily Range (30 D): |
$0.07 | 3.79%
|
| Avg Daily Range (90 D): |
$0.05 | 4.02%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.53M |
| Avg Daily Volume (30 D): |
6.08M |
| Avg Daily Volume (90 D): |
4.62M |
| Trade Size |
| Avg Trade Size (Sh.): |
204 |
| Avg Trade Size (Sh.) (30 D): |
503 |
| Avg Trade Size (Sh.) (90 D): |
439 |
| Institutional Trades |
| Total Inst.Trades: |
2,992 |
| Avg Inst. Trade: |
$1.81M |
| Avg Inst. Trade (30 D): |
$.7M |
| Avg Inst. Trade (90 D): |
$.9M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.26M |
| Avg Closing Trade (30 D): |
$.66M |
| Avg Closing Trade (90 D): |
$.92M |
| Avg Closing Volume: |
108.38K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.8
|
$-.21
|
$-.11
|
|
Diluted EPS
|
$-.8
|
$-.21
|
$-.11
|
|
Revenue
|
$ 259.57M
|
$ 65M
|
$ 69.11M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -153.22M
|
$ -40.46M
|
$ -21.32M
|
|
Operating Income / Loss
|
$ -39.96M
|
$ -22.1M
|
$ -4.42M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -81.85M
|
$ M
|
$ .04M
|
|
PE Ratio
|
|
|
|
|
|
|
